Answers are grounded in this paper and cite their sources.
Demonstrates therapeutic potential of VCU-1012 in neuropsychiatric disorders, suggesting reduced side effects.
Psychedelics that target serotonin 2A receptors (5-HT 2A Rs) hold therapeutic promise for neuropsychiatric disorders but are often hindered by off-target actions. The 5-HT 2A R agonist quipazine also activates 5-HT 3 R, which contributes to undesirable side effects. Here, we developed VCU-1012, a quipazine-based, structurally distinct 5-HT 2A R agonist devoid of 5-HT 3 R activity. VCU-1012 was developed by applying a strategic chemical design that combined deconstruction to pinpoint the nitrogen atom critical for 5-HT 2A R activation with structure-activity relationship studies to minimize 5-HT 3 R agonism. We showed that VCU-1012 modulated dendritic spine structural plasticity in the frontal cortex and produced antidepressant-like effects in mice through 5-HT 2A R without activating 5-HT 3 R, thereby avoiding the gastrointestinal side effects of quipazine. In addition, our molecular modeling and mutant analysis suggested that VCU-1012 interacted in the canonical orthosteric binding pocket of 5-HT 2A R. Together, these findings establish VCU-1012 as a potential therapeutic agent with reduced gastrointestinal impact, emphasize how differences in ligand-receptor interactions influence ligand positioning in the receptor binding pocket, and provide guidance for designing psychedelics with targeted therapeutic benefits.
No takes yet. Share an insight, caveat, or question.
Younkin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: